Introduction And Clinical Rationale

• Pediatric epilepsy affects approximately 1 in 100 children, with Drug-Resistant Epilepsy (DRE) occurring in 20-30% of cases.
• Traditional ASDs frequently fail in focal or genetic epilepsies and cause dose-limiting sedation or behavioral worsening.
• Newer ASDs, specifically Brivaracetam and Cenobamate, offer targeted mechanisms, superior efficacy in focal DRE, and simplified dosing regimens to reduce polytherapy side effects.

Brivaracetam (BRV)

Mechanism Of Action

• Functions as a high-affinity synaptic vesicle protein 2A (SV2A) ligand.
• Exhibits significantly higher selectivity for SV2A compared to levetiracetam (LEV), reducing off-target psychiatric adverse events.

Clinical Efficacy And Tolerability

• Meta-analyses confirm responder rates >50% and seizure freedom rates of 20-40% when used as monotherapy or adjunctive therapy.
• Switching patients from LEV to BRV actively improves behavioral profiles and seizure control.
• Real-world pediatric cohorts report very low discontinuation rates (<12%) for behavioral issues.
• Common adverse effects include mild somnolence and dizziness.

Guidelines And Indications

• AES Guidelines (2026): Conditionally suggests BRV for DRE in infants aged 1 month to <36 months.
• IAP Guidelines (2025–2026): Endorses BRV as adjunctive therapy for focal seizures in children $\ge$ 2 years of age.

Cenobamate

Mechanism Of Action

• A novel monocarbamate utilizing a dual mechanism of action.
• Acts simultaneously via GABA enhancement and direct sodium-channel modulation.

Clinical Efficacy And Tolerability

• Real-world pediatric studies (2025–2026) in DRE (including developmental and epileptic encephalopathies like Lennox-Gastaut) demonstrate 50-84% responder rates and 3-31% absolute seizure freedom.
• Off-label utilization in children <18 years achieved an 80% median seizure reduction and allowed for ASM regimen simplification (e.g., reducing from 5 to 2 concurrent drugs).
• Superior efficacy compared to brivaracetam, lacosamide, and perampanel in focal epilepsy.
• Adverse effects include somnolence and behavioral changes, mandating routine monitoring for suicidality.
• Caution is advised in Dravet syndrome due to possible seizure worsening.

Guidelines And Indications

• NICE Guidelines (2025): Included for refractory focal epilepsy, with pediatric extrapolation supported by 2026 adolescent pharmacokinetic data confirming adult-comparable exposures.
• IAP Guidelines (2025–2026): Emerging as an option for refractory focal DRE in adolescents.

Comparative Overview Of Newer ASDs